EXPI 14.20 First written up at $6.44 with a $7.25 Max buy , later $8.50 EXPI just reported their 1st quarter 2018 results with revenues exploding year over year up 188% and Agent count nearly tripling. Q1 2018 Highlights $62 million in revenue, 188% increase year-over-year Nearly tripled...
Just some quick thoughts for Monday morning on our positions. XON- $14.90, down from $19.19 highs last Thursday on the reaction to the quarterly report. We find the sell off way overdone and purchased a fair amount of shares at a 15.40 average on Friday working...
XON- $17 pre-market 5/11/18 Quarterly Conference Call Transcript (Advised reading) Intrexon reported their quarterly results last night and revenues were lighter than expected, perhaps causing the stock to drop $1.40 in pre-market today. It also dropped from a close breakout over 19 to 18.40 into the close...
AQMS- $3.50 area Conference Call Transcript (Worth a read) Aqua Metals reported their progress and 1st quarter report on May 9th after the market closed. We have just recommended the stock this week to buy from 3.20-3.80 ranges for 1/2 size position allocation. The stock has been...
Brief updates on our 5 open positions: AQMS, XON, CLLS, ADAP, EXPI We are reviewing a micro cap stock to consider next, along with a few other candidates. We have 5 positions, 4 are full at 8% each allocation and one is 4% allocation (AQMS-New) so...
SP 500 Update: Consolidating in Major Wave 4, Wave 5 up could take markets to all time highs in the many months ahead, 2470 key support on LOW END The markets continue to be volatile as we have seen. The SP 500 to wit is in...
The markets continue to try to find footing. The SP 500 at 2616 area was a recent line in the sand pointed out at our SRP service on Sunday this past weekend. So far it has held and this correction has now been going on...
Position and Chart Updates Brief notes and Technical Chart updates on all 5 open positions. CLLS, EXPI, XON, ADAP, CDXC CLLS- $30-$31 area This has been consolidating a bit since the $38 spike price movement on the Allogene partnership news. We have said that we think in time Allogene...
The rough and tumble stock market continues and we are down to 4 open positions in the TPS Portfolio. The obvious aim is to hold 6-18 months, but we also have to mind reasonable downside risk and monitor developments of companies we write reports on. Sometimes...
CLLS- $29 Recently we saw CLLS soar to $38 per share from $31 on news that Pfizer through a new private entity called Allogene Therapeutics was continuing the UCART 19 development program with Cellectis. The same day the stock soared CLLS announced a 5 million share...
indian xxnx horny desi indian cheating slime wife show boobs in webcam.
